Company news
Terns Pharmaceuticals, Inc. (NASDAQ:TERN) news
Terns Pharmaceuticals, Inc. news releases on 6ix. Latest, Mar 14, 2024: Terns Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results…
Press releases — page 2
Terns Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updates
March 13, 2024
Terns Pharmaceuticals Announces Orphan Drug Designation Granted to TERN-701 for the Treatment of Chronic Myeloid Leukemia
March 10, 2024
Terns Pharmaceuticals to Participate in Upcoming March Investor Conferences
February 26, 2024
Terns Pharmaceuticals Reports Inducement Grants to New Chief Executive Officer Under Nasdaq Listing Rule 5635(C)(4)
February 6, 2024
Terns Pharmaceuticals Appoints Amy Burroughs as Chief Executive Officer
February 6, 2024
Terns Pharmaceuticals to Highlight 2024 Priorities and Clinical Milestones at the 42nd Annual J.P. Morgan Healthcare Conference
January 3, 2024
Terns Pharmaceuticals to Present at the JMP Securities Hematology and Oncology Summit
November 28, 2023
Terns Pharmaceuticals Mourns the Loss of Senthil Sundaram, Former Chief Executive Officer
November 26, 2023
Terns Pharmaceuticals Reports Third Quarter 2023 Financial Results and Corporate Updates
November 13, 2023
Terns Pharmaceuticals Presents Late-Breaking Data from Phase 2a DUET Trial of THR-β Agonist TERN-501 in NASH at AASLD The Liver Meeting® 2023
November 12, 2023
Terns Pharmaceuticals Announces First Participant Dosed in Phase 1 Clinical Trial of TERN-601 Oral GLP-1 Receptor Agonist for Treatment of Obesity
November 1, 2023
Terns Pharmaceuticals to Participate in Upcoming Investor Conferences
October 18, 2023
Terns Pharmaceuticals Announces Global Phase 1 Clinical Trial Design of TERN-701 for the Treatment of Chronic Myeloid Leukemia
October 15, 2023
Terns Pharmaceuticals to Participate in Upcoming September Investor Conferences
September 4, 2023
Terns Pharmaceuticals Reports Second Quarter 2023 Financial Results and Corporate Updates
August 7, 2023
Terns Achieves Primary Endpoint and All Secondary Endpoints in Phase 2a DUET Trial of THR-β Agonist TERN-501 in NASH
August 7, 2023
Terns Pharmaceuticals Announces Leadership Transition
August 2, 2023
Terns Pharmaceuticals to Host Virtual Key Opinion Leader Event to Discuss TERN-701 and Advances in the Treatment Landscape for Chronic Myeloid Leukemia
July 17, 2023
Terns Pharmaceuticals Highlights New Preclinical Data for TERN-601 Program in Obesity at the ADA’s 83rd Annual Scientific Session and Upcoming Events
June 25, 2023
Terns Pharmaceuticals to Present at Goldman Sachs 44th Annual Global Healthcare Conference
June 5, 2023
Terns Pharmaceuticals Announces Publication of TERN-701 Trial-in-Progress Abstract for the 2023 ASCO Annual Meeting
May 24, 2023
Terns Pharmaceuticals to Present at Upcoming Investor Conferences
May 23, 2023
Terns Pharmaceuticals to Highlight New Preclinical Data for TERN-601 Program in Obesity at the American Diabetes Association’s 83rd Annual Scientific Sessions
May 21, 2023
Terns Pharmaceuticals Reports First Quarter 2023 Financial Results and Corporate Updates
May 14, 2023
Terns Pharmaceuticals to Participate in the JMP Securities 2023 Life Sciences Conference
May 8, 2023
Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
May 2, 2023
Terns Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Updates
March 26, 2023
Terns Pharmaceuticals Appoints Emil Kuriakose, M.D., as Chief Medical Officer of Terns Oncology
March 26, 2023
Terns Pharmaceuticals Provides Program Updates and Announces Participation at Upcoming March Investor Conferences
March 1, 2023
Terns Pharmaceuticals to Participate in Guggenheim Healthcare Talks 2023 Oncology Conference
February 1, 2023
Terns Pharmaceuticals to Present at B. Riley Securities’ 3rd Annual Oncology Conference
January 11, 2023
Terns Pharmaceuticals to Highlight 2023 Priorities and Clinical Milestones at the 41st Annual J.P. Morgan Healthcare Conference
January 4, 2023
Terns Announces Closing of Public Offering of Shares of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
December 22, 2022
Terns Announces Pricing of $75 Million Public Offering
December 19, 2022
Terns Pharmaceuticals to Present at the 2022 JMP Securities Hematology and Oncology Summit
November 30, 2022
Terns Pharmaceuticals Reports Third Quarter 2022 Financial Results and Corporate Highlights
November 8, 2022
Terns Pharmaceuticals Highlights Results from Phase 1 Clinical Trial of TERN-501 at AASLD The Liver Meeting® 2022
November 3, 2022
Terns Pharmaceuticals to Present Positive Clinical Data in NASH at AASLD The Liver Meeting® 2022
October 25, 2022
Terns Pharmaceuticals to Present at the H. C. Wainwright 6th Annual NASH Investor Conference
October 10, 2022
Terns Pharmaceuticals to Present at the H.C. Wainwright 24th Annual Global Investment Conference
September 6, 2022
Terns Announces $65 Million Oversubscribed Offering
August 11, 2022
Terns Pharmaceuticals Reports Second Quarter 2022 Financial Results and Corporate Highlights
August 7, 2022
Terns Announces Appointment of Radhika Tripuraneni, M.D., M.P.H. to Board of Directors
July 26, 2022
Terns Pharmaceuticals Highlights Clinical Data from Multiple NASH Programs in Five Presentations at the EASL International Liver Congress™ 2022
June 21, 2022
Terns Pharmaceuticals to Present Clinical Data on Multiple NASH Programs at the EASL International Liver Congress 2022
June 7, 2022
Terns Pharmaceuticals Appoints Kerry Russell as Chief Medical Officer
May 31, 2022
Terns Pharmaceuticals Reports First Quarter 2022 Financial Results and Business Updates
May 15, 2022
Terns Pharmaceuticals to Present at the 21st Annual Needham Virtual Healthcare Conference
April 3, 2022
Terns Reports Top-line Results from Phase 1 AVIATION Trial of VAP-1 Inhibitor TERN-201
March 20, 2022
Terns Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Highlights
March 2, 2022